Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine

Cardiovascular Drugs and Therapy

Volumn 23, Issue 5, 2009, Pages 395-401

  Lever, Michael ^a   George, Peter M ^a   Slow, Sandy ^a   Elmslie, Jane L ^a   Scott, Russell S ^b   Richards, A Mark ^c   Fink, John N ^b   Chambers, Stephen T ^c  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Bezafibrate; Fibrate; Homocysteine; Metabolic syndrome; Urine betaine

Indexed keywords

BETAINE; BEZAFIBRATE; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE; URINARY EXCRETION;

ACUTE CORONARY SYNDROME; AGED; ANTILIPEMIC AGENTS; BETAINE; CLOFIBRIC ACID; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; HOMOCYSTEINE; HUMANS; LIPIDS; MALE; S-ADENOSYLMETHIONINE; STROKE;

EID: 72849132109     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-009-6188-1     Document Type: Article

References (35)

1. M Lever PC Sizeland LM Bason CM Hayman RA Robson ST Chambers 1994 Abnormal glycine betaine content of the blood and urine of diabetic and renal patients Clin Chim Acta 230 69 79 10.1016/0009-8981(94)90090-6 1:CAS:528:DyaK2cXmsFarur8%3D 7850995 (Pubitemid 24303650)
2. WJ Dellow ST Chambers M Lever H Lunt RA Robson 1999 Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia Diab Res Clin Pract 43 91 9 10.1016/S0168-8227(98)00115-6 1:CAS:528:DyaK1MXhsVWkt7o%3D (Pubitemid 29155653)
3. M Lever PC Sizeland CM Frampton ST Chambers 2004 Short and long-term variation of plasma glycine betaine concentrations in humans Clin Biochem 37 184 90 10.1016/j.clinbiochem.2003.11.004 1:CAS:528:DC%2BD2cXht1yqsL8%3D 14972639 (Pubitemid 38221565)
4. M Lever PM George WJ Dellow RS Scott ST Chambers 2005 Homocysteine, glycine betaine, and N, N-dimethylglycine in patients attending a lipid clinic Metabolism 54 1 14 10.1016/j.metabol.2004.07.007 1:CAS:528:DC%2BD2cXhtVansb3K 15562374 (Pubitemid 39572451)
5. N Broeders C Knoop M Antoine AD Tielemans 2000 Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15 1993 9 10.1093/ndt/15.12.1993 1:CAS:528:DC%2BD3cXptVeit7c%3D 11096145
6. J Lipscombe GF Lewis D Cattran JM Bargman 2001 Deterioration in renal function associated with fibrate therapy Clin Nephrol 55 39 44 1:CAS:528:DC%2BD3MXhtl2hurc%3D 11200866
7. Y-H Lin K-Y Pao V-C Wu Y-L Lin Y-F Chien C-S Hung Y-U Chen C-P Liu I-J Tsai C-S Gau K-D Wu J-J Hwang 2007 The influence of estimated creatinine clearance on plasma homocysteine in hypertensive patients with normal serum creatinine Clin Biochem 40 230 4 10.1016/j.clinbiochem.2006.11.010 1:CAS:528:DC%2BD2sXntlOgsw%3D%3D 17222811 (Pubitemid 46108715)
8. MH Davidson A Armani JM McKenney TA Jacobson 2007 Safety considerations with fibrate therapy Am J Cardiol 99 3C 18C 10.1016/j.amjcard.2006.11.016 1:CAS:528:DC%2BD2sXjtFGltL4%3D 17368275 (Pubitemid 46412226)
9. EA Brinton 2008 Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Curr Atheroscler Rep 10 25 32 10.1007/s11883-008-0005-3 1:CAS:528:DC%2BD1cXktVKqtbc%3D 18366982
10. C Hottelart N El Esper JM Archard A Pruna A Fournier 1999 Fenofibrate increases blood creatinine, but dies not change the glomerular filtration rate in patients with mild renal insufficiency Nephrologie 20 41 4 1:STN:280:DyaK1M7otVyktA%3D%3D 10081035
11. A Garcia-Perez MB Burg 1991 Renal medullary organic osmolytes Physiol Rev 71 1081 115 1:CAS:528:DyaK38XktVCg 1924548
12. F Schliess D Häussinger 2002 The cellular hydration state: a critical determinant for cell death and survival Biol Chem 383 577 83 10.1515/BC.2002.059 1:CAS:528:DC%2BD38XksVajtL0%3D 12033446 (Pubitemid 34506294)
13. Slow S, Lever M, Chambers ST, George PM. Plasma dependent and independent accumulation of betaine in male and female rat tissues. Physiol Res in press (available on-line as pre-press article 1569).
14. Storer MK. Development of laboratory tests for assessing vitamin status. PhD Thesis, University of Otago, Dunedin, New Zealand 2006.
15. JA De Lemos DA Morrow JH Bentley T Omland MS Sabatine CH McCabe C Hall CP Cannon E Braunwald 2001 The prognostic value of B-type natriuretic peptides in patients with acute coronary syndromes New Engl J Med 345 1014 21 10.1056/NEJMoa011053 11586953 (Pubitemid 34940793)
16. M Lever PC Sizeland LM Bason CM Hayman ST Chambers 1994 Glycine betaine and proline betaine in human blood and urine Biochim Biophys Acta 1200 259 64 1:CAS:528:DyaK2cXmtVWntro%3D 8068711
17. M Lever W Atkinson S Slow ST Chambers PM George 2009 Plasma and urine betaine and dimethylglycine variation in healthy young male subjects Clin Biochem 42 706 12 10.1016/j.clinbiochem.2009.02.001 1:CAS:528: DC%2BD1MXksVaksrk%3D 19217890
18. MK Storer M Lever 2006 Aracyl triflates for preparing fluorescent and UV absorbing derivatives of unreactive carboxylates, amines and other metabolites Anal Chim Acta 558 319 25 10.1016/j.aca.2005.10.060 1:CAS:528: DC%2BD28XotFynuw%3D%3D (Pubitemid 43120522)
19. MK Storer CJ McEntyre M Lever 2006 Separation of cationic aracyl derivatives of betaines and related compounds J Chromatogr A 1104 263 71 10.1016/j.chroma.2005.11.123 1:CAS:528:DC%2BD28XmsVOjsg%3D%3D 16376895 (Pubitemid 43102577)
20. M Lever W Atkinson PM George ST Chambers 2007 Sex differences in the control of plasma concentrations and urinary excretion of glycine betaine in patients attending a lipid disorders clinic Clin Biochem 40 1225 31 10.1016/j.clinbiochem.2007.05.021 1:CAS:528:DC%2BD2sXhtF2iur7F 17706956 (Pubitemid 47562415)
21. SV Konstantinova GS Tell SE Vollset O Nygård ∅ Bleie PM Ueland 2008 Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women J Nutr 138 914 20 1:CAS:528:DC%2BD1cXltFOnt7w%3D 18424601
22. C Hottelart N El Esper F Rose JM Achard A Fournier 2002 Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 536 41 10.1159/000064083 1:CAS:528:DC%2BD38XnslWqtrY%3D 12372935
23. The FIELD study investigators 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 1849 61 10.1016/S0140-6736(05)67667-2 (Pubitemid 41690113)
24. JC Ansquer C Foucher S Rattier MR Taskinen G Steiner 2005 Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 485 93 10.1053/j.ajkd.2004.11.004 1:CAS:528:DC%2BD2MXislOjsbk%3D 15754270 (Pubitemid 40341327)
25. M Lever W Atkinson ST Chambers PM George 2007 An abnormal urinary excretion of glycine betaine may persist for years Clin Biochem 40 798 801 10.1016/j.clinbiochem.2007.03.009 1:CAS:528:DC%2BD2sXntF2rtrs%3D 17490630 (Pubitemid 46961963)
26. GF Watts SB Dimmitt 1999 Fibrates, dyslipoproteinaemia and cardiovascular disease Curr Opin Lipidol 10 561 74 10.1097/00041433-199912000-00011 1:CAS:528:DC%2BD3cXntlCmtw%3D%3D 10680050 (Pubitemid 30064026)
27. PJ Barter K-A Rye 2008 Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28 39 46 10.1161/ATVBAHA.107.148817 1:CAS:528:DC%2BD2sXhsVeiu7nJ 17717290
28. S Luci S Geissler B König A Koch GI Stangl F Hirche K Eder 2006 PPAR-α agonists up-regulate organic cation transporters in rat liver cells Biochem Biophys Res Comm 350 704 8 10.1016/j.bbrc.2006.09.099 1:CAS:528:DC%2BD28XhtVyisbnO 17011512 (Pubitemid 44547904)
29. R Ringseis S Luci J Spielmann H Kluge M Fischer S Geissler G Wen F Hirche K Eder 2008 Clofibrate treatment up-regulates novel organic cation transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species Eur J Pharmacol 583 11 7 10.1016/j.ejphar.2008.01.008 1:CAS:528:DC%2BD1cXivVaqu7c%3D 18258227
30. +-carnitine cotransporter hOCTN2 Am J Physiol Renal Physiol 279 F584 91 1:CAS:528:DC%2BD3cXmvFSjsbo%3D 10966938
31. MR Olthof T van Vliet E Boelsma P Verhoef 2003 Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women J Nutr 133 4135 8 1:CAS:528:DC%2BD3sXpslGmtbs%3D 14652361
32. U Schwab A Torronen E Meririnne M Saarinen G Alfthan A Aro M Uusitupa 2006 Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans J Nutr 136 34 8 1:CAS:528:DC%2BD28XivFSgtg%3D%3D 16365055
33. Taskinen M-R, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol. 2009;29.
34. W Atkinson J Elmslie M Lever ST Chambers PM George 2008 Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and post methionine load conditions in healthy male subjects Am J Clin Nutr 87 577 85 1:CAS:528:DC%2BD1cXjsVagt7k%3D 18326594
35. Atkinson A, Slow S, Elmslie J, Lever M, Chambers ST, George PM. Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males. Nutr Metab Cardiovasc Dis. 2009.